Finding. 2-Hydroxyglutarate tells cells to put fatty acids in the attic. In primary human heart and vessel cells, both D and L enantiomers swell triglyceride droplets and drain phosphatidylethanolamine, mitochondrial oxidation, long-chain acylcarnitines, and lipotoxic leftovers. L2HG does more with less intracellular accumulation: it drives DGAT, slows TG breakdown, and pinches the ethanolamine Kennedy branch. Pseudohypoxia is not required. Mice loaded with L2HG get high serum TGs, remade cardiac TG chains, and less ischemia-triggered acylcarnitine in the heart. Human blood 2HG and TGs move together. The question is no longer whether fat is fuel. It is which bin it goes in.
Why this paper matters
2HG is usually an epigenetic oncometabolite. This paper gives it a lipid-allocation job that reaches mitochondria by starving FAO, and that looks, in ischemia, like a buffer against acylcarnitine pile-up. The price is PE and circulating TGs.
That is a mitochondrial flexibility paper disguised as a metabolite paper.
What they actually measured
Human primary cardiac/vascular cells, both enantiomers, TG/PE/FAO/acylcarnitine/peroxidation, DGAT and Kennedy, omics, mouse lipids and ischemia, human association.
How to read the score
Low eighties. Multi-system, organelle-relevant, honest enantiomer split. Confidence is medium. Score 82.
What to do with it
If you work on 2HG, cardiac lipotoxicity, or FAO, pull the PE and ischemia-acylcarnitine panels. Do not treat 2HG as a cardioprotective drug; hypertriglyceridemia is in the same paragraph. The directional implication is that 2HG expands metabolic flexibility by parking fat in TG and away from mitochondrial oxidation and PE.